Ocugen Completes Enrollment in Pivotal Trial for Gene Therapy Targeting Stargardt Disease
Ocugen (NASDAQ:OCGN) has completed enrollment ahead of schedule in its Phase 2/3 GARDian3 trial for OCU410ST, a gene therapy targeting Stargardt disease. The company expects to release top-line results by Q2 2027 and aims to file a Biologics License Application (BLA) mid-2027.